A new combination of drugs could help delay the advancement of a deadly form of prostate cancer in those with an advanced form of the disease, new research has found. The "striking" findings showed an ...

When I tell a patient he has prostate cancer, this is usually what he asks me first. With early-stage or low-grade prostate cancer, I can offer strong reassurance: Your life expectancy is good — ...

A new drug combo is offering hope for men with advanced prostate cancer. Adding the targeted cancer drug niraparib to hormone therapy reduced the risk of prostate tumor growth and slowed symptom ...

Testing the molecular profile of tumors identifies which patients with advanced prostate cancer are more likely to benefit from chemotherapy and live longer, sparing patients less likely to benefit ...

Men treated for nonmetastatic prostate cancer under current guidelines are up to 6 times less likely to die from their cancer than from other causes, according to data from a Swedish cancer registry.

Adding the targeted cancer drug niraparib to hormone therapy reduced the risk of prostate tumor growth and slowed symptom advance, according to findings published Oct. 7 in the journal Nature Medicine ...